Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Plant Stanol Esters and COVID-19 Vaccination Response

11. februar 2022 oppdatert av: Maastricht University Medical Center

The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine

Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI has previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effect on the immune system, people with overweight or obesity might benefit from consuming plant stanols prior to receiving the COVID-19 vaccination. The primary objective of this study is to demonstrate clinical benefits of consumption of plant stanols (delivered via products enriched with plant stanol esters) on the vaccination response to a COVID-19 vaccine in overweight or obese patients. The main study endpoint is vaccination response to a COVID-19 vaccine. Secondary endpoints include amongst others hematological, inflammatory and immunological parameters (e.g. hs-CRP, leukocyte differential count) and metabolic markers (e.g. blood lipid profiles, plasma glucose, serum insulin, HOMA-IR).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

48

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Limburg
      • Maastricht, Limburg, Nederland, 6229ER
        • Maastricht University Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women
  • Aged 18 years or older
  • BMI between 27 and 35 kg/m2
  • Currently not using products containing plant sterols or stanols (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)
  • Willing to keep the intake of fish oil and vitamin supplements constant

Exclusion Criteria:

  • Already received COVID-19 vaccination
  • Already had a positive test for COVID-19 (this includes all types of tests, e.g. PCR tests or antibody tests)
  • Allergy to an ingredient of the mini drinks
  • Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
  • Pregnant women
  • Breastfeeding women
  • Excessive alcohol use (>20 consumptions per week)
  • Regular use of soft or hard drugs

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Plant stanol group
This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Placebo komparator: Placebo group
This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Vaccine specific antibody titers
Tidsramme: Change T=0 and T= 4 weeks
The response to the COVID-19 vaccine will be measured by quantifying specific antibody titers (vaccine specific IgG and IgM). These titers will be measured in blood samples collected weekly during the month after vaccination by suitable ELISAs.
Change T=0 and T= 4 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Immune parameters (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination
Cytokine production by PBMCs after stimulation with antiCD3-antiCD28 antiCD28 antibodies using the TruCulture system
T=-1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination
Immune parameters (2)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
hsCRP
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Leukocyte count
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Number of leukocytes measured in EDTA plasma
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Leukocyte differential count
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Number of subgroups of leukocytes measured in EDTA plasma
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Fasted metabolism (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Serum non-cholesterol sterols and stanols
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Fasted metabolism (2)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Serum lipid and lipoprotein profile
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Fasted metabolism (3)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Glucose metabolism (including e.g. plasma glucose, serum insulin and calculated HOMA-IR)
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Anthropometry (1)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Body weight
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Anthropometry (2)
Tidsramme: T=-1 (start study)
Height
T=-1 (start study)
Anthropometry (3)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Waist circumference
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Anthropometry (4)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Hip circumference
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Anthropometry (5)
Tidsramme: T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Waist-to-hip ratio
T=-1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)
Diet
Tidsramme: T=-1 (start study) and T=4 weeks after vaccination (end study)
Food frequency questionnaire is used to determine if the participants maintain their habitual diet and to determine if the participants do not consume plant stanols and/or sterols outside the intervention
T=-1 (start study) and T=4 weeks after vaccination (end study)
Diary outcomes (1)
Tidsramme: T=-1 (start study) until T=4 weeks after vaccination (end of study)
General illness
T=-1 (start study) until T=4 weeks after vaccination (end of study)
Diary outcomes (2)
Tidsramme: T=0 (day before vaccination) until T=4 weeks after vaccination (end of study)
Side effects COVID-19 vaccine
T=0 (day before vaccination) until T=4 weeks after vaccination (end of study)
Diary outcomes (3)
Tidsramme: T=-1 (start study) until T=4 weeks after vaccination (end of study)
Medication intake
T=-1 (start study) until T=4 weeks after vaccination (end of study)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. april 2021

Primær fullføring (Faktiske)

11. januar 2022

Studiet fullført (Faktiske)

11. januar 2022

Datoer for studieregistrering

Først innsendt

13. april 2021

Først innsendt som oppfylte QC-kriteriene

13. april 2021

Først lagt ut (Faktiske)

14. april 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. mars 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. februar 2022

Sist bekreftet

1. februar 2022

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere